PRPH
What one share of ProPhase Labs holds
Pharmaceutical Preparations
We are a growth oriented and diversified next generation biotech, genomics and consumer products company that develops and commercializes novel drugs, dietary supplements, and compounds, and human genomic testing.
ProPhase Labs’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $0.29 |
|---|---|
| Profit | −$1.71 |
| Cash and investments | $0.00 |
| Book value | −$0.22 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $2.46 | −$1.68 | $0.38 | −$0.66 | — | $3.49 |
| 2017 | $6.29 | $25.86 | $0.13 | −$1.94 | — | $28.61 |
| 2018 | $11.52 | −$1.53 | $0.12 | −$1.98 | — | $14.28 |
| 2019 | $8.54 | −$2.72 | $0.20 | −$0.92 | — | $9.70 |
| 2020 | $12.52 | −$1.83 | $1.46 | −$3.69 | $0.00 | $9.10 |
| 2021 | $42.97 | $3.95 | $2.30 | −$9.70 | $3.00 | $37.86 |
| 2022 | $65.76 | $10.24 | $2.10 | $13.21 | — | $39.25 |
| 2023 | $20.33 | −$9.75 | $1.21 | −$8.12 | — | $27.37 |
| 2024 | $3.38 | −$26.68 | $0.45 | −$9.22 | — | $2.46 |
| 2025 | $0.51 | −$1.74 | $0.00 | −$0.98 | — | $0.39 |